Congenital Thrombotic Thrombocytopenic Purpura (cTTP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Congenital thrombotic thrombocytopenic purpura (cTTP) is an inherited condition characterized by severe reduction of platelets in the bloodstream, destruction of red blood cells, and varying degrees of organ failure. While most individuals with this condition experience symptoms in infancy or childhood, the severity and specific manifestations can differ significantly. Some individuals may only have mild symptoms of low platelet count throughout childhood. In contrast, others may develop significant jaundice and experience episodes of low platelet count and red blood cell destruction soon after birth. In some cases, the initial onset of TTP occurs during adulthood, particularly in women, and is triggered by pregnancy. Infections and vaccinations can also act as precipitating factors. Congenital TTP is caused by a mutation in the ADAMTS13 gene located on chromosome 9q34. This gene provides instructions for producing ADAMTS13, an enzyme breaking down excessively large von Willebrand factor molecules in the blood. Approximately 50% of individuals with congenital TTP develop a chronic and frequently recurring condition. Recurrent episodes typically characterize congenital TTP over a longer period compared to the immune-mediated form of the disease (iTTP). Both forms of TTP can lead to various complications, including neurological issues, kidney problems, heart dysfunction, and gastrointestinal symptoms, all resulting from the widespread formation of small blood clots in the body's blood vessels. TTP is a rapidly fatal disease without treatment, with a mortality rate exceeding 90%. However, introducing therapeutic plasma exchange and infusion has significantly decreased the mortality rate to around 15%. Plasma therapy is also effective in preventing long-term organ complications resulting from recurrent episodes of TTP.

·       The annual incidence in the USA is 2.99 cases per million annually.

Thelansis’s “Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Thrombotic Thrombocytopenic Purpura (cTTP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Congenital Thrombotic Thrombocytopenic Purpura (cTTP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032